

Select patient examples from the pivotal phase 3 trial⁷

INDIVIDUAL PROFILES WITH A CLINICAL OR LABORATORY DIAGNOSIS CONSISTENT WITH HoFH ⁷					
AGE	GENDER	CV COMORBIDITY	TREATED BASELINE LDL-C	MAXIMALLY TOLERATED LIPID MEDICATIONS	GENETIC ANALYSIS
53	F	<ul style="list-style-type: none"> • Angina pectoris 	172	<ul style="list-style-type: none"> • Atorvastatin 40 mg PO QD 	2 identical receptor mutations or true HoFH
41	F	<ul style="list-style-type: none"> • Aortic bruit • Hypertension • Atherosclerosis native coronary artery 	214	<ul style="list-style-type: none"> • Atorvastatin 80 mg PO QD • Niacin 2000 mg PO QD • Cholestipol 10 mg PO QD • Ezetimibe 10 mg PO QD 	Genetically confirmed HoFH but allelic information not available
38	M	<ul style="list-style-type: none"> • Aortic atheromatosis 	313	<ul style="list-style-type: none"> • Rosuvastatin 40 mg PO QD • Ezetimibe 10 mg PO QD 	2 nonidentical receptor mutations or compound HeFH
38	F	<ul style="list-style-type: none"> • Coronary artery disease • Definite aortic valve stenosis 	492	<ul style="list-style-type: none"> • Atorvastatin 80 mg PO QD • Ezetimibe 10 mg PO QD 	2 nonidentical receptor mutations or compound HeFH
14	F	<ul style="list-style-type: none"> • Probable aortic valve stenosis 	558	<ul style="list-style-type: none"> • Atorvastatin 80 mg PO QD • Ezetimibe 10 mg PO QD 	2 nonidentical receptor mutations or compound HeFH
50	F	<ul style="list-style-type: none"> • Aortic stenosis • Chest pain at high effort • Abdominal systolic murmur 	639	<ul style="list-style-type: none"> • Atorvastatin 80 mg PO QD • Ezetimibe 10 mg PO QD • Nicotinic acid 1000 mg PO BID 	Not available
31	F	<ul style="list-style-type: none"> • Aortic valve stenosis 	704	<ul style="list-style-type: none"> • Atorvastatin 80 mg PO QD • Ezetimibe 10 mg PO QD 	2 identical receptor mutations or true HoFH

BID=twice daily; CV=cardiovascular; PO=orally; QD=once daily.

All patients in phase 3 trial with KYNAMRO® (mipomersen sodium) injection were either genetically or clinically diagnosed as having HoFH.³

Please see additional **Important Safety Information**, including **Boxed Warning**, and full **Prescribing Information** on KYNAMRO.com.

KYNAMRO[®]
(mipomersen sodium) injection
200mg/ml